Devimistat(CPI-613)联合改良氟尿嘧啶、奥沙利铂、伊立替康和亚叶酸钙(FFX)对比FFX治疗转移性胰腺腺癌患者:III期AVENGER 500研究
AVENGER 500是一项全球、随机III期试验,在74个中心、6个国家纳入528例初治转移性胰腺腺癌患者,比较Devimistat联合改良FFX(实验组)与标准剂量FFX(对照组)的疗效与安全性。主要终点总生存期在实验组为11.10个月,对照组为11.73个月(HR 0.95,95%CI 0.77-1.18,P=0.655),无进展生存期分别为7.8个月和8.0个月(HR 0.99,95%CI 0.76-1.29,P=0.94)。结论认为联合Devimistat未改善长期和短期结局,未发现新的毒性信号。
要点
- Devimistat联合mFFX相比标准FFX未改善总生存期(11.10 vs 11.73个月,HR 0.95,P=0.655)。
- 无进展生存期两组分别为7.8个月和8.0个月(HR 0.99,P=0.94),无显著差异。
- ≥3级治疗中出现的不良事件发生率两组相近,未发现新的毒性信号。
核心结论
- Devimistat联合mFFX与标准FFX相比未改善转移性胰腺腺癌患者的长期和短期结局。
- 加用Devimistat未发现新的毒性信号。
研究设计与样本
- AVENGER 500(NCT03504423)是一项全球、随机III期试验,在6个国家74个中心开展。
- 研究纳入528例初治转移性胰腺腺癌患者,随机分配至实验组266例和对照组262例。
- 实验组接受Devimistat 500 mg/m2/天(第1天和第3天静脉给药)联合改良FFX,对照组接受标准剂量FFX,每2周一个周期直至疾病进展或不可耐受毒性。
- 主要终点为总生存期。
主要发现
- 实验组中位总生存期为11.10个月,对照组为11.73个月(HR 0.95,95%CI 0.77-1.18,P=0.655)。
- 实验组中位无进展生存期为7.8个月,对照组为8.0个月(HR 0.99,95%CI 0.76-1.29,P=0.94)。
- 实验组 vs 对照组发生率>10%的≥3级治疗中出现的不良事件:中性粒细胞减少29.0% vs 34.5%,腹泻11.2% vs 19.6%,低钾血症13.1% vs 14.9%,贫血13.9% vs 13.6%,血小板减少11.6% vs 13.6%,乏力10.8% vs 11.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Metastatic pancreatic adenocarcinoma (mPC) remains a difficult-to-treat disease. Fluorouarcil, oxaliplatin, irinotecan, and leucovorin (FFX) is a standard first-line therapy for mPC for patients with a favorable performance status and good organ function. In a phase I study, devimistat (CPI-613) in combination with modified FFX (mFFX) was deemed safe and exhibited promising efficacy in mPC. METHODS: The AVENGER 500 trial (ClinicalTrials.gov identifier: NCT03504423) is a global, randomized phase III trial conducted at 74 sites across six countries to investigate the efficacy and safety of devimistat in combination with mFFX (experimental arm) compared with standard-dose FFX (control arm) in treatment-naïve patients with mPC. Treatment, administered in once-every-2-weeks cycles until disease progression or intolerable toxicity, included intravenous devimistat at 500 mg/m2 total per day on days 1 and 3 in the experimental arm. The primary end point of the study was overall survival (OS). RESULTS: Five hundred and twenty-eight patients were randomly assigned (266 in the experimental arm and 262 in the control arm). The median OS was 11.10 months for devimistat plus mFFX versus 11.73 months for FFX (hazard ratio [HR], 0.95 [95% CI, 0.77 to 1.18]; P = .655) and median progression-free survival was 7.8 months versus 8.0 months, respectively (HR, 0.99 [95% CI, 0.76 to 1.29]; P = .94). Grade ≥3 treatment-emergent adverse events with >10% frequency in the devimistat plus mFFX arm versus the FFX arm were neutropenia (29.0% v 34.5%), diarrhea (11.2% v 19.6%), hypokalemia (13.1% v 14.9%), anemia (13.9% v 13.6%), thrombocytopenia (11.6% v 13.6%), and fatigue (10.8% v 11.5%), respectively. CONCLUSION: Devimistat in combination with mFFX did not improve long- and short-term mPC patient outcomes compared with standard FFX. There were no new toxicity signals with the addition of devimistat.
引用
- Philip PA, Sahai V, Bahary N, et al. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. J Clin Oncol. 2024. PMID: 39088774. doi:10.1200/JCO.23.02659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。